文献速递新药、器械与细胞基因治疗研发基础与转化研究

口服有效且高耐药屏障的流感药物在雪貂及人气道上皮中的特性研究

Characterization of orally efficacious influenza drug with high resistance barrier in ferrets and human airway epithelia.
PubMed 文献 · Sci Transl Med · 2019-01-01

研究开发了核糖核苷类似物N4-羟基胞苷(NHC,EIDD-1931)的异丙酯前药EIDD-2801,其在培养细胞和小鼠中显示广谱抗流感病毒活性。药代动力学分析表明EIDD-2801在雪貂和非人灵长类中口服生物利用度良好。口服治疗可显著降低流感病毒感染的雪貂的病毒载量并缓解症状,暴露后预防给药可达到灭菌效果,深度测序揭示致死性病毒突变是其作用机制,并显示高耐药屏障。

要点

  • EIDD-2801在雪貂和非人灵长类中口服生物利用度良好
  • 治疗性口服给药降低雪貂甲型流感病毒载量多个数量级并缓解发热和炎症
  • 在人气道上皮模型中治疗窗口大于1713,支持其作为临床候选药物

核心结论

  • EIDD-2801具有口服有效性、高耐药屏障和宽治疗窗口,推荐作为季节性及大流行性流感病毒感染的单一治疗临床候选药物。
  • 研究结果为EIDD-2801的临床试验设计和药物暴露目标提供了依据。

研究设计与样本

  • 研究在培养细胞、小鼠、雪貂和非人灵长类中评估EIDD-2801的药代动力学和抗流感病毒活性,并在人气道上皮模型中进行疗效和细胞毒性阈值与药代动力学关联分析。

主要发现

  • EIDD-2801在雪貂和非人灵长类中口服生物利用度良好。
  • 治疗性口服给药使流感病毒感染的雪貂的组大流行1和组2季节性甲型流感病毒排毒载量降低多个数量级,并缓解发热、气道上皮组织病理学和炎症。
  • 暴露后预防给药具有灭菌效果。
  • 深度测序揭示致死性病毒突变是EIDD-2801活性的潜在机制,并显示 prohibitive 的病毒耐药发展屏障。
  • 在疾病相关的高分化人气液界面气道上皮中,对甲型和乙型流感病毒的抑制浓度为低纳摩尔级。

关键数值与推荐

  • EIDD-2801是核糖核苷类似物N4-羟基胞苷(NHC,EIDD-1931)的异丙酯前药。
  • 在疾病相关的高分化人气液界面气道上皮中,对甲型和乙型流感病毒的抑制浓度为低纳摩尔级。
  • 在人气道上皮模型中,治疗窗口大于1713。

临床怎么用

  • 原文未据此给出临床推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Influenza viruses constitute a major health threat and economic burden globally, frequently exacerbated by preexisting or rapidly emerging resistance to antiviral therapeutics. To address the unmet need of improved influenza therapy, we have created EIDD-2801, an isopropylester prodrug of the ribonucleoside analog N 4-hydroxycytidine (NHC, EIDD-1931) that has shown broad anti-influenza virus activity in cultured cells and mice. Pharmacokinetic profiling demonstrated that EIDD-2801 was orally bioavailable in ferrets and nonhuman primates. Therapeutic oral dosing of influenza virus-infected ferrets reduced group pandemic 1 and group 2 seasonal influenza A shed virus load by multiple orders of magnitude and alleviated fever, airway epithelium histopathology, and inflammation, whereas postexposure prophylactic dosing was sterilizing. Deep sequencing highlighted lethal viral mutagenesis as the underlying mechanism of activity and revealed a prohibitive barrier to the development of viral resistance. Inhibitory concentrations were low nanomolar against influenza A and B viruses in disease-relevant well-differentiated human air-liquid interface airway epithelia. Correlating antiviral efficacy and cytotoxicity thresholds with pharmacokinetic profiles in human airway epithelium models revealed a therapeutic window >1713 and established dosing parameters required for efficacious human therapy. These data recommend EIDD-2801 as a clinical candidate with high potential for monotherapy of seasonal and pandemic influenza virus infections. Our results inform EIDD-2801 clinical trial design and drug exposure targets.

来源:Sci Transl Med,查看原文。版权归原作者所有。

引用

  1. Toots M, Yoon JJ, Cox RM, et al. Characterization of orally efficacious influenza drug with high resistance barrier in ferrets and human airway epithelia. Sci Transl Med. 2019. PMID: 31645453. doi:10.1126/scitranslmed.aax5866

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。